(S)-2-((S)-2,6-二氨基己酰氨基)-3-甲基丁酸 | 20556-11-0

• 物质功能分类: 生物化工 - 生化试剂 - 氨基酸
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-2-((S)-2,6-二氨基己酰氨基)-3-甲基丁酸
• 中文别名: L-赖氨酰-L-缬氨酸
• 英文名称: Lys-Val
• 英文别名: Lysylvaline；(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoic acid
• CAS: 20556-11-0
• 化学式: C₁₁H₂₃N₃O₃
• 分子量: 245.322
• InChiKey: YQAIUOWPSUOINN-IUCAKERBSA-N

物化性质

• 沸点：
  496.8±45.0 °C(Predicted)
• 密度：
  1.119±0.06 g/cm3(Predicted)
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  -3.6
• 重原子数：
  17
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.818
• 拓扑面积：
  118
• 氢给体数：
  4
• 氢受体数：
  5

安全信息

• 海关编码：
  2924199090

反应信息

• 作为产物：
  描述：

  Lys-Val-MCA 在 乙二胺四乙酸 、 dipeptydyl-peptidase DPP₅ 、 sodium phosphate 、 sodium chloride 作用下， 以 水 为溶剂， 反应 0.5h， 生成 (S)-2-((S)-2,6-二氨基己酰氨基)-3-甲基丁酸
  参考文献：
  名称：

  Identification and Characterization of Prokaryotic Dipeptidyl-peptidase 5 from Porphyromonas gingivalis

  摘要：

  Background: Dipeptidyl-peptidases (DPPs) are key factors for amino acid metabolism and bacterial growth of asaccharolytic Porphyromonas gingivalis. Results: DPP5, which is specific for Ala and hydrophobic residues, is expressed in the periplasmic space of P. gingivalis.Conclusion: DPP5 was discovered in prokaryotes for the first time. Significance: The discovery of DPP5 expands understanding of amino acid and energy metabolism in prokaryotes. Porphyromonas gingivalis, a Gram-negative asaccharolytic anaerobe, is a major causative organism of chronic periodontitis. Because the bacterium utilizes amino acids as energy and carbon sources and incorporates them mainly as dipeptides, a wide variety of dipeptide production processes mediated by dipeptidyl-peptidases (DPPs) should be beneficial for the organism. In the present study, we identified the fourth P. gingivalis enzyme, DPP5. In a dpp4-7-11-disrupted P. gingivalis ATCC 33277, a DPP7-like activity still remained. PGN_0756 possessed an activity indistinguishable from that of the mutant, and was identified as a bacterial orthologue of fungal DPP5, because of its substrate specificity and 28.5% amino acid sequence identity with an Aspergillus fumigatus entity. P. gingivalis DPP5 was composed of 684 amino acids with a molecular mass of 77,453, and existed as a dimer while migrating at 66 kDa on SDS-PAGE. It preferred Ala and hydrophobic residues, had no activity toward Pro at the P1 position, and no preference for hydrophobic P2 residues, showed an optimal pH of 6.7 in the presence of NaCl, demonstrated K-m and k(cat)/K-m values for Lys-Ala-MCA of 688 m and 11.02 m(-1) s(-1), respectively, and was localized in the periplasm. DPP5 elaborately complemented DPP7 in liberation of dipeptides with hydrophobic P1 residues. Examinations of DPP- and gingipain gene-disrupted mutants indicated that DPP4, DPP5, DPP7, and DPP11 together with Arg- and Lys-gingipains cooperatively liberate most dipeptides from nutrient oligopeptides. This is the first study to report that DPP5 is expressed not only in eukaryotes, but also widely distributed in bacteria and archaea.

  DOI：

  10.1074/jbc.m113.527333

文献信息

• Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes
  申请人：DermBiont, Inc.

  公开号：US11040077B2

  公开（公告）日：2021-06-22

  Disclosed herein are compositions and methods for using human-derived Janthinobacterium lividum. Compositions improve skin health. Methods may include applying human-derived Janthinobacterium lividum over a host or host area, such as skin or mucosa, to minimize the presence of one or more microbes, maximize therapeutic effects, and/or improve health. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-derived Janthinobacterium lividum and an acceptable carrier. Compositions and methods may include a prebiotic to maximize growth and/or metabolites. Compositions and methods may include human-derived Janthinobacterium lividum metabolites, such as violacein, prodigiosin, indole-3-carboxaldehyde, and lantibiotics, and/or other Postbiotics.

  本文公开了使用源自人类的 Lividum Janthinobacterium 的组合物和方法。组合物可改善皮肤健康。方法可包括在宿主或宿主区域（如皮肤或粘膜）上施用源于人的生发的Lividum Janthinobacterium，以最大限度地减少一种或多种微生物的存在，最大限度地提高治疗效果，和/或改善健康状况。减少病原微生物的方法可包括向表面施用一种组合物，该组合物包括来源于人类的Janthinobacterium lividum和一种可接受的载体。组合物和方法可包括益生元，以最大限度地提高生长和/或代谢物。组合物和方法可包括来源于人的猪蓝细菌代谢物，如violacein、prodigiosin、吲哚-3-甲醛、兰特益生菌和/或其他后益生菌。
• COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES
  申请人：DermBiont, Inc.

  公开号：US20200345799A1

  公开（公告）日：2020-11-05

  Disclosed herein are compositions and methods for using human-derived Janthinobacterium lividum . Compositions improve skin health. Methods may include applying human-derived Janthinobacterium lividum over a host or host area, such as skin or mucosa, to minimize the presence of one or more microbes, maximize therapeutic effects, and/or improve health. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-derived Janthinobacterium lividum and an acceptable carrier. Compositions and methods may include a prebiotic to maximize growth and/or metabolites. Compositions and methods may include human-derived Janthinobacterium lividum metabolites, such as violacein, prodigiosin, indole-3-carboxaldehyde, and lantibiotics, and/or other Postbiotics.